Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

Why Achillion Pharmaceuticals Shares Soared in October

An upcoming trial by Johnson & Johnson that includes a key drug from this tiny drugmaker could eventually reward investors.

Johnson & Johnson's (NYSE:JNJ) decision to launch a mid-stage study evaluating a slate of hepatitis C drugs that includes Achillion Pharmaceuticals' (NASDAQ:ACHN) ACH-3102 could lead to a best-in-class hepatitis C therapy down the road.

In the following slideshow, I outline what you need to know about this trial and why it matters to Achillion Pharmaceuticals' investors.

Todd Campbell owns shares of ACHILLION PHARMACEUTICALS, INC. and Gilead Sciences. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Author

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.
Follow @ebcapital